Cargando…

P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report

POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:    : In this article, we have reported a case of invasive aspergillosis in an 8-year-old boy with chronic granulomatous disease, who presented with pleural effusion and pneumonia, cerebral venous sinus thrombosis, and unusual skin lesions (Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmadi, Bahram, Sarvestani, Hasti Kamali, Ansari, Saham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516259/
http://dx.doi.org/10.1093/mmy/myac072.P212
_version_ 1784798668977602560
author Ahmadi, Bahram
Sarvestani, Hasti Kamali
Ansari, Saham
author_facet Ahmadi, Bahram
Sarvestani, Hasti Kamali
Ansari, Saham
author_sort Ahmadi, Bahram
collection PubMed
description POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:    : In this article, we have reported a case of invasive aspergillosis in an 8-year-old boy with chronic granulomatous disease, who presented with pleural effusion and pneumonia, cerebral venous sinus thrombosis, and unusual skin lesions (Fig. 1) caused by Aspergillus fumigatus (Fig. 2). The patient received recombinant human interferon-γ subcutaneously (1-2 doses in even days) and antimicrobial prophylaxis, including itraconazole (100 mg/d), cotrimoxazole (5 mg trimethoprim/kg body weight/d), and ofloxacin (3 times a week, 200 mg), during hospitalization. It is noteworthy that treatment was immediately started according to the direct examination results. Due to the MRI findings suggestive of brain abscesses and brain edema, empirical amphotericin and voriconazole were started. The in vitro antifungal susceptibility tests (AFST) of A. fumigatus utilized the microbroth dilution method of the Clinical and Laboratory Standards Institute (CLSI) M38-A2 protocol for five antifungal agents including; voriconazole, itraconazole, fluconazole, caspofungin, and amphotericin B, that the minimum inhibitory concentrations (MIC) of antifungal agents were 0.25, 1, 16, 0.125, and 4 mg/L, respectively. Voriconazole and caspofungin were shown to be the most potent antifungal drugs against this A. fumigatus strain. On the other hand, the IDSA protocols recommend voriconazole as the initial therapy of invasive aspergillosis in most patients. So, in response to the results of antifungal susceptibility testing, treatment was switched to voriconazole at the dose of 100 mg twice a day (taken every 12 h), and interferon-γ subcutaneously (1-3 doses in even days) was introduced. Unfortunately, the patient passed away due to cerebral venous sinus thrombosis (CVST), and intracerebral hemorrhage (ICH) following increased intracranial pressure (ICP) after 1 month. In conclusion, we have reported a case in which a patient who came with pleural effusion and pneumonia in the chest x-ray, CVST, and unusual skin lesion caused by A. fumigatus expired after one month. Our report suggests the importance of early diagnosis in children presenting with invasive fungal infections particularly, those involving the central nervous system.
format Online
Article
Text
id pubmed-9516259
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95162592022-09-29 P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report Ahmadi, Bahram Sarvestani, Hasti Kamali Ansari, Saham Med Mycol Oral Presentations POSTER SESSION 2, SEPTEMBER 22, 2022, 12:30 PM - 1:30 PM:    : In this article, we have reported a case of invasive aspergillosis in an 8-year-old boy with chronic granulomatous disease, who presented with pleural effusion and pneumonia, cerebral venous sinus thrombosis, and unusual skin lesions (Fig. 1) caused by Aspergillus fumigatus (Fig. 2). The patient received recombinant human interferon-γ subcutaneously (1-2 doses in even days) and antimicrobial prophylaxis, including itraconazole (100 mg/d), cotrimoxazole (5 mg trimethoprim/kg body weight/d), and ofloxacin (3 times a week, 200 mg), during hospitalization. It is noteworthy that treatment was immediately started according to the direct examination results. Due to the MRI findings suggestive of brain abscesses and brain edema, empirical amphotericin and voriconazole were started. The in vitro antifungal susceptibility tests (AFST) of A. fumigatus utilized the microbroth dilution method of the Clinical and Laboratory Standards Institute (CLSI) M38-A2 protocol for five antifungal agents including; voriconazole, itraconazole, fluconazole, caspofungin, and amphotericin B, that the minimum inhibitory concentrations (MIC) of antifungal agents were 0.25, 1, 16, 0.125, and 4 mg/L, respectively. Voriconazole and caspofungin were shown to be the most potent antifungal drugs against this A. fumigatus strain. On the other hand, the IDSA protocols recommend voriconazole as the initial therapy of invasive aspergillosis in most patients. So, in response to the results of antifungal susceptibility testing, treatment was switched to voriconazole at the dose of 100 mg twice a day (taken every 12 h), and interferon-γ subcutaneously (1-3 doses in even days) was introduced. Unfortunately, the patient passed away due to cerebral venous sinus thrombosis (CVST), and intracerebral hemorrhage (ICH) following increased intracranial pressure (ICP) after 1 month. In conclusion, we have reported a case in which a patient who came with pleural effusion and pneumonia in the chest x-ray, CVST, and unusual skin lesion caused by A. fumigatus expired after one month. Our report suggests the importance of early diagnosis in children presenting with invasive fungal infections particularly, those involving the central nervous system. Oxford University Press 2022-09-20 /pmc/articles/PMC9516259/ http://dx.doi.org/10.1093/mmy/myac072.P212 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Ahmadi, Bahram
Sarvestani, Hasti Kamali
Ansari, Saham
P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title_full P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title_fullStr P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title_full_unstemmed P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title_short P212 Fatal invasive aspergillosis in a child with Chronic Granulomatous disease; a case report
title_sort p212 fatal invasive aspergillosis in a child with chronic granulomatous disease; a case report
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516259/
http://dx.doi.org/10.1093/mmy/myac072.P212
work_keys_str_mv AT ahmadibahram p212fatalinvasiveaspergillosisinachildwithchronicgranulomatousdiseaseacasereport
AT sarvestanihastikamali p212fatalinvasiveaspergillosisinachildwithchronicgranulomatousdiseaseacasereport
AT ansarisaham p212fatalinvasiveaspergillosisinachildwithchronicgranulomatousdiseaseacasereport